Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

POM - Pomdoctor Limited So'nggi Yangiliklar | Finranks

Home

/

POM

P

Pomdoctor Limited (POM)

NGM – Real vaqt narxi. Valyuta: USD

0.94

-0.08 (-7.56%)

Bozor ochiq: Aug 12, 2026, 12:56 PM EDT

0.98

-0.04 (-3.73%)

Oldingi bozordan keyin: Aug 11, 2026, 7:46 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a closed-loop growth model that integrates AI, wearable devices, healthcare data, professional medical services, and insurance payment networks. The Company believes this model enables each healthcare service cycle to generate incremental data, continuously strengthen AI analytics, enhance service personalization, and boost user engagement.

POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure

POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure

Anchoring Established Healthcare Operations to Technology-Enabled Growth Opportunities GUANGZHOU, China, Aug. 3, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its four-tier diversified revenue structure, which is designed to build on the Company's established healthcare operations while developing scalable, technology-enabled services. The Company's four-tier revenue structure consists of B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, along with pharmaceutical real-world study ("RWS") and real-world data ("RWD") services.

Videolar

No Data

There is no data to display

Press-relizlar

POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a closed-loop growth model that integrates AI, wearable devices, healthcare data, professional medical services, and insurance payment networks. The Company believes this model enables each healthcare service cycle to generate incremental data, continuously strengthen AI analytics, enhance service personalization, and boost user engagement.

POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure

POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure

Anchoring Established Healthcare Operations to Technology-Enabled Growth Opportunities GUANGZHOU, China, Aug. 3, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its four-tier diversified revenue structure, which is designed to build on the Company's established healthcare operations while developing scalable, technology-enabled services. The Company's four-tier revenue structure consists of B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, along with pharmaceutical real-world study ("RWS") and real-world data ("RWD") services.